{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:42:07Z","timestamp":1792190527710,"version":"4.4.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-interleukin (IL)-17 treatments have revolutionized psoriasis treatment, offering excellent clinical outcomes and safety profiles. However, these drugs have been associated with class-specific side effects, including Candida infections and eczematous reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the frequency of Candida infections and cutaneous eczematous eruptions in patients with plaque psoriasis treated with secukinumab, ixekizumab, brodalumab or bimekizumab and to identify risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicentre, retrospective, observational study was conducted involving patients with plaque psoriasis treated with anti-IL-17 biologics at five outpatient clinics in Lazio, Italy. Demographic data, clinical data, treatment characteristics and adverse events were analysed. Cox regression models were used to identify factors associated with the occurrence of these adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 1075 patients, 34 (3.2%) developed eczema, and 36 (3.3%) had candidiasis. Treatment was discontinued in 78% of patients who developed eczema and 50% of patients who had candidiasis. Multivariate analysis showed that ixekizumab [hazard ratio (HR) 3.45, P = 0.05] and atopic history (HR 5.43, P = 0.023) were significantly correlated with eczema, while bimekizumab (HR 23.30, P = 0.002) was significantly associated with candidiasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Anti-IL-17 treatments show varying risks of causing side effects such as eczema and candidiasis. Personalized strategies, regular monitoring and prophylactic measures are essential to improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llaf271","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T07:56:30Z","timestamp":1750319790000},"page":"2185-2191","source":"Crossref","is-referenced-by-count":12,"title":["Predictive factors for eczematous eruptions and candidiasis during anti-interleukin-17 treatment in patients with psoriasis: a multicentre real-life experience in Lazio region, Italy"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8837-9232","authenticated-orcid":false,"given":"Giacomo","family":"Caldarola","sequence":"first","affiliation":[{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS , Rome ,","place":["Italy"]},{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"De Luca","sequence":"additional","affiliation":[{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS , Rome ,","place":["Italy"]},{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-6187","authenticated-orcid":false,"given":"Simone","family":"Amato","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Belcastro","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u2018Tor Vergata\u2019 , Rome ,","place":["Italy"]},{"name":"Dermatology Unit, Azienda Ospedaliera Universitaria \u2018Policlinico Tor Vergata\u2019 , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6295-3574","authenticated-orcid":false,"given":"Nicoletta","family":"Bernardini","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u2018Daniele Innocenzi\u2019, Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome , Polo Pontino ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u2018Tor Vergata\u2019 , Rome ,","place":["Italy"]},{"name":"Dermatology Unit, Azienda Ospedaliera Universitaria \u2018Policlinico Tor Vergata\u2019 , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Dattola","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"De Simone","sequence":"additional","affiliation":[{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS , Rome ,","place":["Italy"]},{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Moretta","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Istituto Dermopatico dell\u2019Immacolata IDI-IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabatino","family":"Pallotta","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Istituto Dermopatico dell\u2019Immacolata IDI-IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS , Rome ,","place":["Italy"]},{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Richetta","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimondo","family":"Rossi","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevena","family":"Skroza","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u2018Daniele Innocenzi\u2019, Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome , Polo Pontino ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-5175","authenticated-orcid":false,"given":"Marco","family":"Galluzzo","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u2018Tor Vergata\u2019 , Rome ,","place":["Italy"]},{"name":"Dermatology Unit, Azienda Ospedaliera Universitaria \u2018Policlinico Tor Vergata\u2019 , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"2025102707121279000_llaf271-B1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/14712598.2019.1555235","article-title":"Anti-IL17 therapies for psoriasis","volume":"19","author":"Silfvast-Kaiser","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"2025102707121279000_llaf271-B2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"2025102707121279000_llaf271-B3","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/1744666X.2020.1679625","article-title":"Anti IL-17 in psoriasis","volume":"15","author":"Ly","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"2025102707121279000_llaf271-B4","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/14712598.2020.1727439","article-title":"Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature","volume":"20","author":"Caldarola","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2025102707121279000_llaf271-B5","doi-asserted-by":"crossref","first-page":"100266","DOI":"10.1016\/j.lanepe.2021.100266","article-title":"Risk of candidiasis associated with interleukin-17 inhibitors: a real-world observational study of multiple independent sources","volume":"13","author":"Davidson","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"2025102707121279000_llaf271-B6","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/ced.15052","article-title":"Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?","volume":"47","author":"Megna","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"2025102707121279000_llaf271-B7","doi-asserted-by":"crossref","first-page":"e70040","DOI":"10.1111\/myc.70040","article-title":"Fungal infections associated with TNF-inhibitors: a 20-year of a systematic review fungal infections and TNF-inhibitors","volume":"68","author":"Barbosa","year":"2025","journal-title":"Mycoses"},{"key":"2025102707121279000_llaf271-B8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0001-7310(14)70016-X","article-title":"IL-17 and infections","volume":"105","author":"Ling","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"2025102707121279000_llaf271-B9","doi-asserted-by":"crossref","first-page":"2442603","DOI":"10.1155\/2022\/2442603","article-title":"Risk of Candida infection and serious infections in patients with moderate-to-severe psoriasis receiving biologics: a systematic review and meta-analysis of randomized controlled trials","volume":"2022","author":"Feng","year":"2022","journal-title":"Int J Clin Pract"},{"key":"2025102707121279000_llaf271-B10","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00403-025-04188-w","article-title":"Risk of fungal infection in psoriasis patients treated with IL-17 and IL-23 inhibitors: a multi-cohort study using real-world data","volume":"317","author":"Islam","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"2025102707121279000_llaf271-B11","first-page":"34","article-title":"Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment","volume":"22","author":"Mastorino","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025102707121279000_llaf271-B12","doi-asserted-by":"crossref","first-page":"1341708","DOI":"10.3389\/fimmu.2023.1341708","article-title":"Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses\u00a0\u2013\u200c\u00a0IL PSO (Italian landscape psoriasis)","volume":"14","author":"Gargiulo","year":"2024","journal-title":"Front Immunol"},{"key":"2025102707121279000_llaf271-B13","first-page":"355","article-title":"Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J)","volume-title":"J Dermatol","author":"Saeki","year":"2017"},{"key":"2025102707121279000_llaf271-B14","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.16736","article-title":"Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis","volume":"179","author":"Ryan","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025102707121279000_llaf271-B15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40266-018-0520-z","article-title":"Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies","volume":"35","author":"K\u00f6rber","year":"2018","journal-title":"Drugs Aging"},{"key":"2025102707121279000_llaf271-B16","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/1346-8138.12668","article-title":"Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-\u00adcontrolled, phase 3 study","volume":"41","author":"Ohtsuki","year":"2014","journal-title":"J Dermatol"},{"key":"2025102707121279000_llaf271-B17","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/bjd.17779","article-title":"Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition","volume":"181","author":"Napolitano","year":"2019","journal-title":"Br J Dermatol"},{"key":"2025102707121279000_llaf271-B18","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front Immunol"},{"key":"2025102707121279000_llaf271-B19","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1684\/ejd.2020.3904","article-title":"Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema","volume":"30","author":"Kimura","year":"2020","journal-title":"Eur J Dermatol"},{"key":"2025102707121279000_llaf271-B20","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1111\/jdv.15156","article-title":"Paradoxical eczematous reaction to ixekizumab","volume":"33","author":"Munera-Campos","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025102707121279000_llaf271-B21","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/bjd.16126","article-title":"Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristics","volume":"178","author":"Stoffel","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025102707121279000_llaf271-B22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000235582","article-title":"Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients","volume":"219","author":"Esmailzadeh","year":"2009","journal-title":"Dermatology"},{"key":"2025102707121279000_llaf271-B23","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/bjd.20527","article-title":"Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab","volume":"185","author":"Brunner","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025102707121279000_llaf271-B24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/diagnostics12010003","article-title":"Oral Candida infection in psoriatic patients treated with il17a inhibitors: report of 3 cases and a comprehensive review of the literature","volume":"12","author":"Pettas","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"2025102707121279000_llaf271-B25","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"2025102707121279000_llaf271-B26","doi-asserted-by":"crossref","first-page":"1294416","DOI":"10.3389\/fimmu.2023.1294416","article-title":"Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"2025102707121279000_llaf271-B27","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/ced\/llae400","article-title":"The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: a 16-week multicentre real-world \u00adexperience\u00a0\u2013\u200c\u00a0IL PSO (Italian Landscape Psoriasis)","volume":"50","author":"Megna","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"2025102707121279000_llaf271-B28","doi-asserted-by":"crossref","first-page":"1243843","DOI":"10.3389\/fmed.2023.1243843","article-title":"Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study\u00a0\u2013 \u200cIL PSO (Italian landscape psoriasis)","volume":"10","author":"Gargiulo","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2025102707121279000_llaf271-B29","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/pds.5132","article-title":"Risk of common infections among individuals with psoriasis in Sweden: a nationwide cohort study comparing secukinumab to ustekinumab","volume":"29","author":"Srinivas","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025102707121279000_llaf271-B30","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/09546634.2018.1528000","article-title":"Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain","volume":"30","author":"Notario","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"2025102707121279000_llaf271-B31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/14712598.2020.1708897","article-title":"In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-\u00adsevere plaque psoriasis","volume":"20","author":"Galluzzo","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2025102707121279000_llaf271-B32","doi-asserted-by":"crossref","first-page":"648","DOI":"10.2340\/00015555-2900","article-title":"Initial results of secukinumab drug survival in patients with psoriasis: a multicentre daily practice cohort study","volume":"98","author":"van den Reek","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"2025102707121279000_llaf271-B33","first-page":"125","article-title":"Secukinumab in psoriasis: a single-center experience","volume":"55","author":"A\u011fao\u011flu","year":"2021","journal-title":"Turkderm-Turk Arch Dermatol Venereol"},{"key":"2025102707121279000_llaf271-B34","doi-asserted-by":"crossref","first-page":"993057","DOI":"10.3389\/fimmu.2023.993057","article-title":"Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"2025102707121279000_llaf271-B35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/21501203.2023.2265664","article-title":"Risk of candidiasis associated with interleukin-17 inhibitors: implications and management","volume":"15","author":"Bilal","year":"2023","journal-title":"Mycology"},{"key":"2025102707121279000_llaf271-B36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjd.15015","article-title":"Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management","volume":"177","author":"Saunte","year":"2017","journal-title":"Br\u00a0J Dermatol"},{"key":"2025102707121279000_llaf271-B37","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s13555-022-00687-0","article-title":"A practical guide to the management of oral candidiasis in patients with plaque psoriasis receiving treatments that target interleukin-17","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025102707121279000_llaf271-B38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/mi.2014.57","article-title":"IL-17-mediated antifungal defense in the oral mucosa is independent of neutrophils","volume":"8","author":"Trautwein-Weidner","year":"2015","journal-title":"Mucosal Immunol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf271\/63528640\/llaf271.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/11\/2185\/63528640\/llaf271.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/11\/2185\/63528640\/llaf271.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:12:22Z","timestamp":1761563542000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/11\/2185\/8169429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6,19]]},"published-print":{"date-parts":[[2025,10,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf271","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,6,19]]}}}